Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system.

Elliott HL, Lloyd SM, Ford I, Meredith PA.

Blood Press. 2016;25(2):67-73. doi: 10.3109/08037051.2015.1127526. Epub 2016 Jan 22.

PMID:
26796694
2.

Importance of sustained and "tight" blood pressure control in patients with high cardiovascular risk.

Meredith PA, Lloyd SM, Ford I, Elliott HL.

Blood Press. 2016;25(2):74-82. doi: 10.3109/08037051.2015.1127528. Epub 2016 Jan 21.

PMID:
26796355
3.

Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort.

Fulton RL, Walters MR, Morton R, Touyz RM, Dominiczak AF, Morrison DS, Padmanabhan S, Meredith PA, McInnes GT, Dawson J.

Hypertension. 2015 May;65(5):1008-14. doi: 10.1161/HYPERTENSIONAHA.114.04945. Epub 2015 Mar 23.

PMID:
25801870
4.

Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable?

Elliott HL, Meredith PA.

World J Cardiol. 2014 Jun 26;6(6):507-13. doi: 10.4330/wjc.v6.i6.507.

5.
6.

Are fixed-dose combination antihypertensives suitable as first-line therapy?

Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L.

Curr Med Res Opin. 2012 Oct;28(10):1685-97. doi: 10.1185/03007995.2012.729505. Epub 2012 Sep 26. Review.

PMID:
22978777
7.

Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS.

Toal CB, Meredith PA, Elliott HL.

Blood Press. 2012 Jul;21 Suppl 1:3-10. doi: 10.3109/08037051.2012.690615. Epub 2012 Jul 5. Review.

8.

Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses.

Toal CB, Meredith PA, Elliott HL.

Int J Clin Pharmacol Ther. 2012 Mar;50(3):202-17.

PMID:
22373833
9.

Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.

Meredith PA, Jarvis SC.

Int J Clin Pract. 2011 Aug;65(8):911; author reply 912. doi: 10.1111/j.1742-1241.2011.02700.x. No abstract available.

PMID:
21762314
10.

Improving blood pressure control in patients with diabetes mellitus and high cardiovascular risk.

Elliott HL, Lloyd SM, Ford I, Meredith PA.

Int J Hypertens. 2011 Jan 10;2010:490769. doi: 10.4061/2010/490769.

11.

Angiotensin-receptor blockade, cancer, and concerns.

Meredith PA, McInnes GT.

Lancet Oncol. 2010 Sep;11(9):819; author reply 821-2. doi: 10.1016/S1470-2045(10)70163-7. No abstract available.

PMID:
20816377
12.

Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the "ACTION" database.

Meredith PA, Elliott HL.

Adv Ther. 2010 May;27(5):297-306. doi: 10.1007/s12325-010-0029-2. Epub 2010 May 20.

PMID:
20490733
13.
14.

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.

Meredith PA, Murray LS, McInnes GT.

J Hum Hypertens. 2010 Aug;24(8):525-31. doi: 10.1038/jhh.2009.99. Epub 2009 Dec 17.

PMID:
20016523
15.

Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.

Meredith PA.

Curr Med Res Opin. 2009 Sep;25(9):2179-89. doi: 10.1185/03007990903116867. Review.

PMID:
19601710
16.

Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.

Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ.

J Am Coll Cardiol. 2008 Dec 9;52(24):2000-7. doi: 10.1016/j.jacc.2008.09.011.

17.

The relationships between initial blood pressure and the response to different antihypertensive agents.

Meredith PA, Murray LS, McInnes GT.

J Hypertens. 2007 Dec;25(12):2513-4; author reply 2514. No abstract available.

PMID:
17984676
18.
19.

From hypertension to heart failure -- are there better primary prevention strategies?

Meredith PA, Ostergren J.

J Renin Angiotensin Aldosterone Syst. 2006 Jun;7(2):64-73. Review.

PMID:
17083060
20.
22.
23.

A putative placebo comparison of the SCOPE and LIFE trials.

Meredith PA, Murray LS, McMurray JJ; SCOPE trial; LIFE trial.

J Renin Angiotensin Aldosterone Syst. 2004 Jun;5(2):59-63.

PMID:
15295716
25.

Antihypertensive treatment: full 24 hour control and trough to peak ratio.

Meredith PA.

Cardiologia. 1999 Dec;44 Suppl 1(Pt 1):339-43. Review. No abstract available.

PMID:
12497931
26.

Therapy in the elderly hypertensive.

Meredith PA, Trenkwalder P.

J Renin Angiotensin Aldosterone Syst. 2002 Sep;3 Suppl 1:S49-56. Review. No abstract available.

PMID:
12428220
27.

A chronotherapeutic approach to effective blood pressure management.

Meredith PA.

J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4 Suppl 1):15-9. Review.

28.

Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.

Meredith PA.

Blood Press Suppl. 2001;(3):11-7. Review.

PMID:
11683472
29.

Is postural hypotension a real problem with antihypertensive medication?

Meredith PA.

Cardiology. 2001;96 Suppl 1:19-24. Review.

PMID:
11574742
30.

Evaluation of an antihypertensive therapy utilising meta-analysis of a clinical trial database.

Meredith PA.

J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S1-6.

PMID:
11347855
31.

Angiotensin II receptor antagonists: new paradigms in the treatment of hypertension. Introduction.

Meredith PA, Weber MA.

Blood Press Suppl. 2001;1:4-5. No abstract available.

PMID:
11333012
32.

ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertension.

Meredith PA.

Heart. 2000 Sep;84 Suppl 1:i39-41; discussion i50. No abstract available.

33.

Intrinsically long-acting agents compared with long-acting chronoformulations.

Meredith PA.

Blood Press Monit. 2000;5 Suppl 1:S25-30. Review.

PMID:
10904239
34.

The chronotherapeutics of hypertension

Meredith PA.

Blood Press Monit. 2000;5 Suppl 1:S1. No abstract available.

PMID:
10904235
35.

The importance of sustained blood pressure control.

Meredith PA.

J Cardiovasc Pharmacol. 2000;35 Suppl 3:S7-11. Review.

PMID:
10854045
36.

Trough: peak ratio and smoothness index for antihypertensive agents.

Meredith PA.

Blood Press Monit. 1999 Oct;4(5):257-62. Review.

PMID:
10547647
37.

Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan.

Meredith PA.

Am J Cardiol. 1999 Jul 22;84(2A):7K-12K. Review.

PMID:
10437738
38.

Is cancer related to hypertension or to its treatment?

Lever AF, Hole DJ, Gillis CR, McInnes GT, Meredith PA, Murray LS, Reid JL.

Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):937-46. Review.

PMID:
10423115
39.

Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why?

Lever AF, Beevers DG, Hole DJ, Isles CG, Meredith PA, Murray LS, McInnes GT, Reid JL.

Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):553-62.

PMID:
10423081
40.

ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans.

Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL.

Circulation. 1998 Nov 17;98(20):2148-53.

PMID:
9815869
41.

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW.

Lancet. 1998 Jul 18;352(9123):179-84.

PMID:
9683206
42.

How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoring.

Meredith PA.

J Cardiovasc Pharmacol. 1998;31 Suppl 2:S17-21. Review.

PMID:
9605597
43.

Role of trough to peak efficacy in the evaluation of antihypertensive therapy.

Meredith PA.

J Hypertens Suppl. 1998 Jan;16(1):S59-64. Review.

PMID:
9534099
44.

Cancer risk of hypertensive patients taking calcium antagonists.

Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Robertson JW, Lever AF.

J Hypertens. 1998 Jan;16(1):119-24.

PMID:
9533425
45.

Enhancing patients' compliance. Electronic monitoring approaches should be more widely used.

Meredith PA.

BMJ. 1998 Jan 31;316(7128):393-4; author reply 394. No abstract available.

46.

Clinical relevance of optimal pharmacokinetics in the treatment of hypertension.

Meredith PA.

J Hypertens Suppl. 1997 Dec;15(5):S27-31. Review.

PMID:
9481613
47.

Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.

Elliott HL, Meredith PA.

Drugs Aging. 1997 Dec;11(6):470-9. Review.

PMID:
9413704
48.

Evaluation of endpoints in hypertension: blood pressure.

Meredith PA, Elliott HL.

Blood Press Suppl. 1997;2:86-90. Review.

PMID:
9495634
49.
50.

Calcium-channel blockers and cancer.

Elliott HL, Meredith PA.

Lancet. 1996 Oct 26;348(9035):1165-6; author reply 1167. No abstract available.

PMID:
8888183

Supplemental Content

Loading ...
Support Center